Bălută Monica, Vintilă V, Vintilă M
St. Pantelimon University Emergency Hospital, Department of Internal Medicine and Cardiology, Bucharest, Romania.
Rom J Intern Med. 2004;42(2):277-88.
The number of people with diabetes grows worldwide. The complications resulting from this disease are a significant cause of morbidity and mortality. World Health Organization estimates that, while in the year 2000 the number of people with diabetes was about 177 million, by 2025, this will increase to at least 300 million. The diabetes epidemic, without primary prevention, will continue to grow. Individuals with type 2 diabetes are at a significantly higher risk for coronary heart disease, peripheral vascular disease, and stroke, and they have a greater probability of having hypertension, dyslipidemia, and obesity. A number of clinical trials provide evidences that RAAS inhibition could be helpful at preventing new onset of type 2 diabetes mellitus. Pharmacologic treatment that antagonize the renin-angiotensin system (RAS) provide more benefits, not only in patients after myocardial infarction and in congestive heart failure, but also in persons with hypertension and type 2 diabetes mellitus.
全球糖尿病患者人数不断增加。这种疾病引发的并发症是发病和死亡的一个重要原因。世界卫生组织估计，2000年糖尿病患者人数约为1.77亿，到2025年，这一数字将增至至少3亿。若无一级预防措施，糖尿病流行态势将持续加剧。2型糖尿病患者患冠心病、外周血管疾病和中风的风险显著更高，且患高血压、血脂异常和肥胖症的可能性也更大。多项临床试验表明，抑制肾素-血管紧张素-醛固酮系统（RAAS）可能有助于预防2型糖尿病的新发。拮抗肾素-血管紧张素系统（RAS）的药物治疗不仅对心肌梗死后患者和充血性心力衰竭患者有益，对高血压和2型糖尿病患者也有益。
